• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:00:31 AM ET
    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIOX alert in real time by email
    SC 13G/A 1 zk2125591.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G

     (Amendment No. 3)*

    Sio Gene Therapies Inc.
    (Name of Issuer)

    Common Stock, $0.00001 par value
     (Title of Class of Securities)

    829399104
     (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 829399104
    13G
    Page 2 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Funds Management Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
     ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
     ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    2


    CUSIP No. 829399104
    13G
    Page 3 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare GP Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
     ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
     ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO

    3


    CUSIP No. 829399104
    13G
    Page 4 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
     ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See instructions)
     
    CO

    4


    CUSIP No. 829399104
    13G
    Page 5 of 10 Pages
    1
    NAME OF REPORTING PERSONS
     
    Moshe Arkin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
    ---

    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    IN

    5


    Item 1. (a)
    Name of Issuer:

    Sio Gene Therapies Inc.

                 (b)
    Address of Issuer's Principal Executive Offices:

    130 West 42nd Street, 26th Floor, New York, New York 10036

    Item 2. (a)
    Name of Person Filing:

    Sphera Funds Management Ltd.

    Sphera Global Healthcare GP Ltd.

    Sphera Global Healthcare Management LP

    Moshe Arkin


    (b)
    Address of Principal Business Office:

    Sphera Funds Management Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

    Sphera Global Healthcare GP Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

    Sphera Global Healthcare Management LP – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

    Moshe Arkin – 6 Hachoshlim St., Herzelia, Israel


    (c)
    Citizenship:

    Sphera Funds Management Ltd. – Israel

    Sphera Global Healthcare GP Ltd. – Israel

    Sphera Global Healthcare Management LP – Israel

    Moshe Arkin – Israel


    (d)
    Title of Class of Securities:

    Common Stock, $0.00001 par value


    (e)
    CUSIP Number:

    829399104

    Item 3.
    Not applicable.

    6


    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.


    (b)
    Percent of class:

    See row 11 of cover page of each reporting person


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.

    7

    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    8

     SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 10, 2021
     
     
    Moshe Arkin

    /s/ Moshe Arkin
    ____________________
    By: Moshe Arkin
     
    Sphera Funds Management Ltd.

    /s/ Ori Goldfarb
    ____________________
    By: Ori Goldfarb
    Title: Chief Executive Officer

    Sphera Global Healthcare GP Ltd.

    /s/ Ori Goldfarb
    ____________________
    By: Ori Goldfarb
    Title: Chief Executive Officer

    Sphera Global Healthcare Management LP

    /s/ Doron Breen
    ____________________
    By: Doron Breen
    Title: Managing Partner

    9


    EXHIBIT NO. DESCRIPTION

    Exhibit 1
    Joint Filing Agreement by and among the Reporting Persons, dated as of December 19, 2018 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on December 20, 2018).

    10
    Get the next $SIOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIOX

    DatePrice TargetRatingAnalyst
    2/1/2022$10.00 → $7.00Buy
    HC Wainwright & Co.
    2/1/2022$6.00 → $1.00Outperform → Market Perform
    SVB Leerink
    10/21/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    8/12/2021$7.00 → $6.00Outperform
    SVB Leerink
    7/12/2021$12.50Buy
    Chardan Capital Markets
    More analyst ratings

    $SIOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Meswani Parag V

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:07:32 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Nassif David W.

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:05:27 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Meswani Parag V claimed ownership of 33,733 shares

      3 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/7/22 7:17:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

      PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th

      2/2/24 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

      –  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination

      2/14/23 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

      NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti

      12/14/22 4:49:43 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Financials

    Live finance-specific insights

    See more
    • Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

      Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres

      10/21/21 5:30:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020

      - Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo

      2/9/21 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $7.00 from $10.00 previously

      2/1/22 8:21:09 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Sio Gene Therapies from Outperform to Market Perform and set a new price target of $1.00 from $6.00 previously

      2/1/22 6:26:53 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      10/21/21 12:26:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/13/23 8:53:10 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sio Gene Therapies Inc.

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/10/23 4:00:19 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/14/22 1:57:46 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Sio Gene Therapies Inc.

      15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 4:04:47 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sio Gene Therapies Inc.

      EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 12:15:08 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Sio Gene Therapies Inc.

      POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/17/23 4:15:20 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care